In this week’s video, Dr. Brian G.M. Durie discusses the Black Swan Research Initiative’s 3 “Cure” trials, which use new treatment protocols.

BOTTOM LINE:
Using new treatment protocols with MRD-negativity and negative PET/CT scans as endpoints, there is a strong possibility that we will identify patients as cured.

Have a question? Submit it to [email protected]

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to [email protected]!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at [email protected]

 

 

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Previous Post
Second Asian Myeloma Network Summit in Beijing, China Is a Big Success
Next Post
ASCENT Trial to Treat High-Risk Smoldering Multiple Myeloma Launching Across the US

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.